Mobilization is the recruitment of hematopoietic
stem cells (HSC) into peripheral blood from the bone marrow following
chemotherapy treatment. There are several advantages for reinfusion of
autologous mobilized peripheral blood stem cells over bone marrow HSC.
Access
More About This Research at:
Some of the
major advantages include enhanced immune reconstitution, shorter duration of
granulocytopenia, shorter hospital stays, reduced morbidity and mortality and
saving of financial resources.
Request
to Get the Sample Pages at:
Several
factors, such as type and dose of cytokines, age, mobilizing chemotherapy
regimen, interval from last chemotherapy cycle and type of previous
chemotherapy cycles or radiation, affects HSC mobilization. BioLineRx Ltd. is
developing BL-8040, a short peptide which acts as a CXCR4 antagonist, for the
treatment of HSC mobilization. Celldex Therapeutics Inc., and Aviara
Pharmaceuticals Inc. are some other key players having pipeline drugs for HSC
mobilization.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment